RESEARCH PAPER
Topiramate for smoking cessation: Systematic review and meta-analysis
Nesma Lotfy 1  
,  
 
 
More details
Hide details
1
High Institute of Public Health, Alexandria University, Alexandria, Egypt
CORRESPONDING AUTHOR
Nesma Lotfy   

High Institute of Public Health, Alexandria University, 165 El-Horeya Road, Alexandria Governorate, Egypt
Publication date: 2020-02-24
Submission date: 2019-09-21
Final revision date: 2019-12-04
Acceptance date: 2019-12-09
 
Tob. Prev. Cessation 2020;6(February):14
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Topiramate is an antiepileptic drug that has been used for many labeled and off-labeled indications. It may be useful in reducing withdrawal symptoms of various addictive agents such as alcohol, cocaine, cannabis and smoking. To date, some studies have examined the effectiveness of topiramate for smoking cessation. The present review aims to synthesize the results from those studies and determine topiramate effectiveness in smoking cessation.

Methods:
A comprehensive search was conducted in the databases: PubMed/ Medline, Cochrane, Egyptian Knowledge Bank, and Google Scholar. All clinical trials that examined the effect of topiramate, compared with the placebo, on smoking cessation rate were included. Statistical analysis using fixed effect models, heterogeneity and sensitivity analysis were conducted using RevMan 5.3.

Results:
Five trials met the inclusion criteria and were included in the metaanalysis. Topiramate non-significantly increased prolonged smoking abstinence rate (OR=1.19, 95% CI: 0.57–2.5) compared with the placebo. On the other hand, topiramate significantly increased the abstinence rate at weeks 4, 6, 8 and 12 (OR=3.07, 95% CI: 1.19–7.93; OR=4.03, 95% CI: 1.98–8.2; OR=2.29, 95% CI: 1.23–4.28; and OR=2.45, 95% CI: 1.37–4.39; respectively) compared with the placebo.

Conclusions:
Based on the five trials, where publication bias cannot be excluded, the current evidence is not sufficient to show a significant difference to favor topiramate in prolonged smoking cessation over the placebo, although the 12th week point prevalence favored topiramate.

CONFLICTS OF INTEREST
The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none was reported.
FUNDING
There was no source of funding for this research.
AUTHORS' CONTRIBUTIONS
Search idea: HE. Search strategy and selection criteria: HE and NL. Risk of bias assessment: HE and NL. Meta-analysis: HE and NL. All time-points meta-analysis (ATM) : NL. Writing up of original draft: HE and NL. Review: MH. Writing the final manuscript: NL.
PROVENANCE AND PEER REVIEW
Not commissioned; externally peer reviewed.
 
REFERENCES (36)
1.
Mokdad AH, Marks JS, Stroup DF, Gerberding JL. Actual causes of death in the United States, 2000. JAMA. 2004;291(10):1238-1245. doi:10.1001/jama.291.10.1238
 
2.
National Center for Chronic Disease Prevention and Health Promotion (US) Office on Smoking and Health. The health consequences of smoking—50 years of progress: a report of the Surgeon General. Atlanta (GA): Centers for Disease Control and Prevention (US); 2014. doi:10.1111/dar.12309
 
3.
Langtry HD, Gillis JC, Davis R. Topiramate. Drugs. 1997;54(5):752-773. doi:10.2165/00003495-199754050-00009
 
4.
Marcotte D. Use of topiramate, a new anti-epileptic as a mood stabilizer. J Affect Disord. 1998;50(2-3):245-251. doi:10.1016/s0165-0327(98)00110-4
 
5.
Appolinario JC, Fontenelle LF, Papelbaum M, Bueno JR, Coutinho W. Topiramate use in obese patients with binge eating disorder: an open study. Can J Psychiatry. 2002;47(3):271-273. doi:10.1177/070674370204700309
 
6.
Diener HC, Tfelt-Hansen P, Dahlöf C, et al. Topiramate in migraine prophylaxis. Journal of Neurology. 2004;251(8):943-950. doi:10.1007/s00415-004-0464-6
 
7.
Johnson BA, Ait-Daoud N, Wang X-Q, et al. Topiramate for the treatment of cocaine addiction: a randomized clinical trial. JAMA Psychiatry. 2013;70(12):1338-1346. doi:10.1001/jamapsychiatry.2013.2295
 
8.
Kampman KM, Pettinati HM, Lynch KG, Spratt K, Wierzbicki MR, O’Brien CP. A double-blind, placebo-controlled trial of topiramate for the treatment of comorbid cocaine and alcohol dependence. Drug Alcohol Depend. 2013;133(1):94-99. doi:10.1016/j.drugalcdep.2013.05.026
 
9.
Miranda Jr R, Treloar H, Blanchard A, et al. Topiramate and motivational enhancement therapy for cannabis use among youth: a randomized placebo‐controlled pilot study. Addict Biol. 2017;22(3):779-790. doi:10.1111/adb.12350
 
10.
Schulz KF, Altman DG, Moher D. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340(1):c332-c332. doi:10.1136/bmj.c332
 
11.
Higgins JPT, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343(2):d5928-d5928. doi;10.1136/bmj.d5928
 
12.
Peters JL, Mengersen KL. Meta-analysis of repeated measures study designs. J Eval Clin Pract. 2008;14(5):941-950. doi:10.1111/j.1365-2753.2008.01010.x
 
13.
Liang W, Zhang HM, Zhang HY. [Smoking cessation efficacy of topiramate in patients with depression]. Chinese Journal of New Drugs and Clinical Remedies. 2008;12.
 
14.
Johnson BA, Ait-Daoud N, Akhtar FZ, Javors MA. Use of oral topiramate to promote smoking abstinence among alcohol-dependent smokers: a randomized controlled trial. Arch Intern Med. 2005;165(14):1600-1605. doi:10.1001/archinte.165.14.1600
 
15.
Anthenelli RM, Heffner JL, Wong E, et al. A randomized trial evaluating whether topiramate aids smoking cessation and prevents alcohol relapse in recovering alcohol‐dependent men. Alcohol Clin Exp Res. 2017;41(1):197-206. doi:10.1111/acer.13279
 
16.
Anthenelli RM, Blom TJ, McElroy SL, Keck PE. Preliminary evidence for gender‐specific effects of topiramate as a potential aid to smoking cessation. Addiction. 2008;103(4):687-694. doi:10.1111/j.1360-0443.2008.02148.x
 
17.
Oncken C, Arias AJ, Feinn R, et al. Topiramate for smoking cessation: a randomized, placebo-controlled pilot study. Nicotine Tob Res. 2013;16(3):288-296. doi:10.1093/ntr/ntt141
 
18.
Syed BA, Chaudhari K. Smoking cessation drugs market. Nature Publishing Group. 2013;12(2):97-98. doi:10.1038/nrd3914
 
19.
Moore TJ, Singh S, Furberg CD. The FDA and new safety warnings. Arch Intern Med. 2012;172(1):78-80. doi:10.1001/archinternmed.2011.618
 
20.
Hughes JR, Stead LF, Lancaster T. Nortriptyline for smoking cessation: a review. Nicotine Tob Res. 2005;7(4):491-499. doi:10.1080/14622200500185298
 
21.
Gourlay SG, Stead LF, Benowitz N. Clonidine for smoking cessation. Cochrane Database Syst Rev. 2004;(3):CD000058. doi:10.1002/14651858.cd000058
 
22.
Stead LF, Koilpillai P, Fanshawe TR, Lancaster T. Combined pharmacotherapy and behavioural interventions for smoking cessation. Cochrane Database Syst Rev. 2016(3):CD008286. doi:10.1002/14651858.CD008286.pub2
 
23.
Jones M. Topiramate-safety and tolerability. Can J Neurol Sci. 1998;25(3):S13-S15. doi:10.1017/s0317167100034855
 
24.
Shorvon SD. Safety of topiramate: adverse events and relationships to dosing. Epilepsia. 1996;37:S18-S22. doi:10.1111/j.1528-1157.1996.tb06029.x
 
25.
Zawertailo L, Mansoursadeghi-Gilan T, Zhang H, Hussain S, Le Foll B, Selby P. Varenicline and Bupropion for Long-Term Smoking Cessation (the MATCH Study): Protocol for a Real-World, Pragmatic, Randomized Controlled Trial. JMIR Res Protoc. 2018;7(10):e10826. doi:10.2196/10826
 
26.
Zenteno RJH, Lara DF, Venegas AR, et al. Varenicline for long term smoking cessation in patients with COPD. Pulm Pharmacol Ther. 2018;53:116-120. doi:10.1016/j.pupt.2018.11.001
 
27.
Ashare RL, Thompson M, Serrano K, et al. Placebo-controlled randomized clinical trial testing the efficacy and safety of varenicline for smokers with HIV. Drug Alcohol Depend. 2019;200:26-33. doi:10.1016/j.drugalcdep.2019.03.011
 
28.
Baltieri DA, Daró FR, Ribeiro PL, de Andrade AG. Effects of topiramate or naltrexone on tobacco use among male alcohol-dependent outpatients. Drug Alcohol Depend. 2009;105(1-2):33-41. doi:10.1016/j.drugalcdep.2009.05.025
 
29.
Isgro M, Doran N, Heffner JL, et al. Type A/Type B alcoholism predicts differential response to topiramate in a smoking cessation trial in dually diagnosed men. J Stud Alcohol Drugs. 2017;78(2):232-240. doi:10.15288/jsad.2017.78.232
 
30.
Worley MJ, Isgro M, Heffner JL, Lee SY, Daniel BE, Anthenelli RM. Predictors of reduced smoking quantity among recovering alcohol dependent men in a smoking cessation trial. Addict Behav. 2018;84:263-270. doi:10.1016/j.addbeh.2018.05.004
 
31.
Weinberger AH, George TP, Perkins KA, Chengappa KR. Effects of topiramate on smoking in patients with schizoaffective disorder, bipolar type. J Clin Psychopharmacol. 2008;28(2):247-248. doi:10.1097/jcp.0b013e31816740cf
 
32.
Vaughan B, Mariani JJ, Pavlicova M, et al. Secondary analysis of smoking rates from a double-blind, placebo-controlled clinical trial of mixed-amphetamine salts and topiramate for cocaine dependence. Drug Alcohol Depend. 2015;100(146):e10. doi:10.1016/j.drugalcdep.2014.09.709
 
33.
Campayo JG, Sobradiel N, Alda M, et al. Effectiveness of topiramate for tobacco dependence in patients with depression; a randomised, controlled trial. BMC Fam Pract. 2008;9(1):28. doi:10.1186/1471-2296-9-28
 
34.
Reid MS, Palamar J, Raghavan S, Flammino F. Effects of topiramate on cue-induced cigarette craving and the response to a smoked cigarette in briefly abstinent smokers. Psychopharmacology. 2007;192(1):147-158. doi:10.1007/s00213-007-0755-6
 
35.
Sofuoglu M, Poling J, Mouratidis M, Kosten T. Effects of topiramate in combination with intravenous nicotine in overnight abstinent smokers. Psychopharmacology. 2006;184(3-4):645-651. doi:10.1007/s00213-005-0296-9
 
36.
Khazaal Y, Cornuz J, Bilancioni R, Zullino DF. Topiramate for smoking cessation. Psychiatry Clin Neurosci. 2006;60(3):384-388. doi:10.1111/j.1440-1819.2006.01518.x
 
eISSN:2459-3087